secondary myelofibrosis
Information
- Disease name
- secondary myelofibrosis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00095784 | Active, not recruiting | Phase 2 | Decitabine in Treating Patients With Myelofibrosis | September 29, 2004 | February 22, 2025 |
| NCT01644110 | Active, not recruiting | Phase 1/Phase 2 | Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF | August 2013 | April 2026 |
| NCT02251821 | Active, not recruiting | Phase 2 | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | October 20, 2014 | December 28, 2025 |
| NCT02370329 | Active, not recruiting | Phase 2 | P1101 in Treating Patients With Myelofibrosis | August 12, 2015 | August 2024 |
| NCT04339101 | Active, not recruiting | Phase 2 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | November 11, 2020 | May 22, 2024 |
| NCT00424242 | Completed | Early Phase 1 | Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases | January 2007 | September 2011 |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00445900 | Completed | Phase 2 | Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia | October 2004 | October 2006 |
| NCT00589563 | Completed | Phase 2 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | May 2007 | February 2012 |
| NCT00611351 | Completed | Phase 2 | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | June 7, 2005 | September 17, 2008 |
| NCT00669578 | Completed | Phase 1/Phase 2 | CC-4047 in Treating Patients With Myelofibrosis | May 2008 | December 12, 2019 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01731951 | Completed | Phase 2 | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | October 29, 2012 | May 24, 2018 |
| NCT01732445 | Completed | Phase 2 | Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis | April 2013 | August 10, 2017 |
| NCT02098161 | Completed | Phase 2 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | December 18, 2014 | May 19, 2022 |
| NCT02917096 | Completed | Phase 1 | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis | November 13, 2016 | August 31, 2023 |
| NCT03426969 | Completed | Early Phase 1 | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | January 31, 2018 | September 21, 2020 |
| NCT00438958 | Completed | Phase 3 | Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases | March 2007 | |
| NCT00423826 | No longer available | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease | January 2007 | January 2015 | |
| NCT03118492 | Recruiting | Phase 1 | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis | May 24, 2017 | March 24, 2025 |
| NCT05364762 | Recruiting | Phase 2 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | November 23, 2022 | April 28, 2024 |
| NCT05393674 | Recruiting | Phase 2 | Fedratinib in Combination With Nivolumab | June 14, 2022 | June 30, 2026 |
| NCT04370301 | Recruiting | Phase 2 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | February 9, 2021 | August 31, 2029 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT04384692 | Recruiting | Phase 2 | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis | December 18, 2020 | December 31, 2029 |
| NCT00722254 | Terminated | Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | June 2006 | February 2009 | |
| NCT00589602 | Terminated | Phase 2 | T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases | January 2004 | December 2014 |
| NCT00630994 | Terminated | Phase 2 | Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis | March 2008 | April 2012 |
| NCT00381693 | Terminated | Phase 2 | Azacitidine in Treating Patients With Myelofibrosis | August 2006 | April 2009 |
| NCT00376519 | Terminated | Phase 1 | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | May 2007 | March 2008 |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT03303950 | Terminated | Phase 2 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | March 30, 2018 | February 19, 2020 |
| NCT02528877 | Withdrawn | Phase 1 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | November 2015 |